Skip to main content
Erschienen in: Endocrine 3/2011

01.12.2011 | Original Article

Association between the T869C polymorphism of transforming growth factor-beta 1 and diabetic nephropathy: a meta-analysis

verfasst von: Hongxia Jia, Lili Yu, Bin Gao, Qiuhe Ji

Erschienen in: Endocrine | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Accumulating evidence has suggested that transforming growth factor-beta 1 (TGF-β1) is a functional candidate for diabetic nephropathy (DN). However, association studies investigating the relationship of TGF-β1 gene T869C polymorphism and DN generate inconsistent results. To comprehensively clarify this issue, we performed a meta-analysis to evaluate the impact of the polymorphism on DN. We searched studies from PubMed and China National Knowledge Infrastructure (CNKI) through March 2011. Pooled ORs were calculated under allelic/additive/dominant/recessive/over-dominant genetic models. Nine studies with 1776 cases and 1740 controls were included. Our results indicated that C allele of T869C conferred a significantly increased risk of DN compared with T allele (OR = 1.25, 95% CI: 1.05–1.48) for allelic contrast. Similar results were also found under additive (OR = 1.57, 95% CI: 1.10–2.23) and dominant (OR = 1.40, 95% CI: 1.06–1.85) genetic models. However, subgroup analyses stratified by types of diabetes showed that significantly increased risks were only observed in type 2 diabetic patients, and the association persistently existed in further analysis for Asian populations. As for type 1 diabetic subjects, no significant association was detected under all the genetic models (P > 0.05). Our meta-analysis suggested that the TGF-β1 T869C polymorphism conferred an elevated risk of DN. However, significant associations were only observed in type 2 diabetic patients.
Literatur
1.
Zurück zum Zitat A. Jawa, J. Kcomt, V.A. Fonseca, Diabetic nephropathy and retinopathy. Med. Clin. North. Am. 88, 1001–1036 (2004)PubMedCrossRef A. Jawa, J. Kcomt, V.A. Fonseca, Diabetic nephropathy and retinopathy. Med. Clin. North. Am. 88, 1001–1036 (2004)PubMedCrossRef
2.
Zurück zum Zitat G. Remuzzi, A. Schieppati, P. Ruggenenti, Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346, 1145–1151 (2002)PubMedCrossRef G. Remuzzi, A. Schieppati, P. Ruggenenti, Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346, 1145–1151 (2002)PubMedCrossRef
3.
Zurück zum Zitat S. Yamagishi, K. Fukami, S. Ueda, S. Okuda, Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 8, 952–959 (2007)PubMedCrossRef S. Yamagishi, K. Fukami, S. Ueda, S. Okuda, Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 8, 952–959 (2007)PubMedCrossRef
4.
Zurück zum Zitat F.N. Ziyadeh, Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res. Clin. Pract. 82, S38–S41 (2008)PubMedCrossRef F.N. Ziyadeh, Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res. Clin. Pract. 82, S38–S41 (2008)PubMedCrossRef
5.
Zurück zum Zitat T. Yamamoto, T. Nakamura, N.A. Noble, E. Ruoslahti, W.A. Border, Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA 90, 1814–1818 (1993)CrossRef T. Yamamoto, T. Nakamura, N.A. Noble, E. Ruoslahti, W.A. Border, Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA 90, 1814–1818 (1993)CrossRef
6.
Zurück zum Zitat J.B. Kopp, V.M. Factor, M. Mozes, P. Nagy, N. Sanderson, E.P. Bottinger, P.E. Klotman, S.S. Thorgeirsson, Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab. Investig. 74, 991–1003 (1996)PubMed J.B. Kopp, V.M. Factor, M. Mozes, P. Nagy, N. Sanderson, E.P. Bottinger, P.E. Klotman, S.S. Thorgeirsson, Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab. Investig. 74, 991–1003 (1996)PubMed
7.
Zurück zum Zitat F.N. Ziyadeh, B.B. Hoffman, D.C. Han, M.C. Iglesias-De La Cruz, S.W. Hong, M. Isono, S. Chen, T.A. McGowan, K. Sharma, Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97, 8015–8020 (2000)PubMedCrossRef F.N. Ziyadeh, B.B. Hoffman, D.C. Han, M.C. Iglesias-De La Cruz, S.W. Hong, M. Isono, S. Chen, T.A. McGowan, K. Sharma, Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97, 8015–8020 (2000)PubMedCrossRef
8.
Zurück zum Zitat K. Sharma, Y. Jin, J. Guo, F.N. Ziyadeh, Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45, 522–530 (1996)PubMedCrossRef K. Sharma, Y. Jin, J. Guo, F.N. Ziyadeh, Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45, 522–530 (1996)PubMedCrossRef
9.
Zurück zum Zitat D. Fujii, J.E. Brissenden, R. Derynck, U. Francke, Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat. Cell Mol. Genet. 12, 281–288 (1986)PubMedCrossRef D. Fujii, J.E. Brissenden, R. Derynck, U. Francke, Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat. Cell Mol. Genet. 12, 281–288 (1986)PubMedCrossRef
10.
Zurück zum Zitat Y. Yamada, A. Miyauchi, J. Goto, Y. Takagi, H. Okuizumi, M. Kanematsu, M. Hase, H. Takai, A. Harada, K. Ikeda, Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res. 13, 1569–1576 (1998)PubMedCrossRef Y. Yamada, A. Miyauchi, J. Goto, Y. Takagi, H. Okuizumi, M. Kanematsu, M. Hase, H. Takai, A. Harada, K. Ikeda, Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J. Bone Miner. Res. 13, 1569–1576 (1998)PubMedCrossRef
11.
Zurück zum Zitat M.M. Jahromi, B.A. Millward, A.G. Demaine, Significant correlation between association of polymorphism in codon 10 of transforming growth factor-beta1 T (29) C with type 1 diabetes and patients with nephropathy disorder. J. Interf. Cytokine Res. 30, 59–66 (2010)CrossRef M.M. Jahromi, B.A. Millward, A.G. Demaine, Significant correlation between association of polymorphism in codon 10 of transforming growth factor-beta1 T (29) C with type 1 diabetes and patients with nephropathy disorder. J. Interf. Cytokine Res. 30, 59–66 (2010)CrossRef
12.
Zurück zum Zitat E. Zintzaras, J.P. Ioannidis, Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28, 123–137 (2005)PubMedCrossRef E. Zintzaras, J.P. Ioannidis, Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28, 123–137 (2005)PubMedCrossRef
13.
Zurück zum Zitat J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002)PubMedCrossRef J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002)PubMedCrossRef
14.
Zurück zum Zitat J.L. Fleiss, The statistical basis of meta-analysis. Stat. Methods Med. Res. 2, 121–145 (1993)PubMedCrossRef J.L. Fleiss, The statistical basis of meta-analysis. Stat. Methods Med. Res. 2, 121–145 (1993)PubMedCrossRef
15.
Zurück zum Zitat F. Pociot, P.M. Hansen, A.E. Karlsen, B.L. Langdahl, J. Johannesen, J. Nerup, TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. J. Am. Soc. Nephrol. 9, 2302–2307 (1998)PubMed F. Pociot, P.M. Hansen, A.E. Karlsen, B.L. Langdahl, J. Johannesen, J. Nerup, TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. J. Am. Soc. Nephrol. 9, 2302–2307 (1998)PubMed
16.
Zurück zum Zitat S. Nair, A.O. Phillips, N. Norton, G. Spurlock, H.J. Williams, K.J. Craig, J.D. Williams, N.M. Williams, T. Bowen, Further evidence for the association of MMP9 with nephropathy in type 2 diabetes and application of DNA pooling technology to candidate gene screening. J. Nephrol. 21, 400–405 (2008)PubMed S. Nair, A.O. Phillips, N. Norton, G. Spurlock, H.J. Williams, K.J. Craig, J.D. Williams, N.M. Williams, T. Bowen, Further evidence for the association of MMP9 with nephropathy in type 2 diabetes and application of DNA pooling technology to candidate gene screening. J. Nephrol. 21, 400–405 (2008)PubMed
17.
Zurück zum Zitat P. Prasad, A.K. Tiwari, K.M. Kumar, A.C. Ammini, A. Gupta, R. Gupta, B.K. Thelma, Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med. Genet. 8, 20–25 (2007)PubMedCrossRef P. Prasad, A.K. Tiwari, K.M. Kumar, A.C. Ammini, A. Gupta, R. Gupta, B.K. Thelma, Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med. Genet. 8, 20–25 (2007)PubMedCrossRef
18.
Zurück zum Zitat Y. Akai, H. Sato, H. Ozaki, M. Iwano, Y. Dohi, M. Kanauchi, Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am. J. Kidney Dis. 38, S182–S185 (2001)PubMedCrossRef Y. Akai, H. Sato, H. Ozaki, M. Iwano, Y. Dohi, M. Kanauchi, Association of transforming growth factor-beta1 T29C polymorphism with the progression of diabetic nephropathy. Am. J. Kidney Dis. 38, S182–S185 (2001)PubMedCrossRef
19.
Zurück zum Zitat A. Patel, W.R. Scott, P.A. Lympany, J.D. Rippin, G.V. Gill, A.H. Barnett, S.C. Bain, The TGF-beta 1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in Type 1 diabetes. Diabet. Med. 22, 69–73 (2005)PubMedCrossRef A. Patel, W.R. Scott, P.A. Lympany, J.D. Rippin, G.V. Gill, A.H. Barnett, S.C. Bain, The TGF-beta 1 gene codon 10 polymorphism contributes to the genetic predisposition to nephropathy in Type 1 diabetes. Diabet. Med. 22, 69–73 (2005)PubMedCrossRef
20.
Zurück zum Zitat T.Y. Wong, P. Poon, K.M. Chow, C.C. Szeto, M.K. Cheung, P.K. Li, Association of transforming growth factor-beta (TGF-beta) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. Kidney Int. 63, 1831–1835 (2003)PubMedCrossRef T.Y. Wong, P. Poon, K.M. Chow, C.C. Szeto, M.K. Cheung, P.K. Li, Association of transforming growth factor-beta (TGF-beta) T869C (Leu 10Pro) gene polymorphisms with type 2 diabetic nephropathy in Chinese. Kidney Int. 63, 1831–1835 (2003)PubMedCrossRef
21.
Zurück zum Zitat T.S. Ahluwalia, M. Khullar, M. Ahuja, H.S. Kohli, A. Bhansali, V. Mohan, R., Venkatesan, T.S. Rai, K. Sud, P.K. Singal, Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4, e5168 (2009). T.S. Ahluwalia, M. Khullar, M. Ahuja, H.S. Kohli, A. Bhansali, V. Mohan, R., Venkatesan, T.S. Rai, K. Sud, P.K. Singal, Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4, e5168 (2009).
22.
Zurück zum Zitat A.J. McKnight, D.A. Savage, C.C. Patterson, D. Sadlier, A.P. Maxwell, Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy. BMC Med. Genet. 8, 5–15 (2007)PubMedCrossRef A.J. McKnight, D.A. Savage, C.C. Patterson, D. Sadlier, A.P. Maxwell, Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy. BMC Med. Genet. 8, 5–15 (2007)PubMedCrossRef
23.
Zurück zum Zitat M. Buraczynska, I. Baranowicz-Gaszczyk, E. Borowicz, A. Ksiazek, TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron Physiol 106, 69–75 (2007)CrossRef M. Buraczynska, I. Baranowicz-Gaszczyk, E. Borowicz, A. Ksiazek, TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron Physiol 106, 69–75 (2007)CrossRef
24.
Zurück zum Zitat D.P. Ng, J.H. Warram, A.S. Krolewski, TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants. Am. J. Kidney Dis. 41, 22–28 (2003)PubMedCrossRef D.P. Ng, J.H. Warram, A.S. Krolewski, TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: an investigation of multiple known DNA sequence variants. Am. J. Kidney Dis. 41, 22–28 (2003)PubMedCrossRef
25.
Zurück zum Zitat A. Valladares-Salgado, J. Angeles-Martinez, M. Rosas, J. Garcia-Mena, D. Utrera-Barillas, R. Gomez-Diaz, J. Escobedo-de la Pena, E.J. Parra, M. Cruz, Association of polymorphisms within the transforming growth factor-beta1 gene with diabetic nephropathy and serum cholesterol and triglyceride concentrations. Nephrology (Carlton) 15, 644–648 (2010)CrossRef A. Valladares-Salgado, J. Angeles-Martinez, M. Rosas, J. Garcia-Mena, D. Utrera-Barillas, R. Gomez-Diaz, J. Escobedo-de la Pena, E.J. Parra, M. Cruz, Association of polymorphisms within the transforming growth factor-beta1 gene with diabetic nephropathy and serum cholesterol and triglyceride concentrations. Nephrology (Carlton) 15, 644–648 (2010)CrossRef
26.
Zurück zum Zitat Y.S. Wei, Y. Lan, Y.W. You, R.G. Tang, Y. Huang, L. Zhang, B. Luo, The serum level and the genotype of TGF-β1 in patients with type 2 diabetic nephropathy. Chin. J. Lab. Med. 28, 73–77 (2005) Y.S. Wei, Y. Lan, Y.W. You, R.G. Tang, Y. Huang, L. Zhang, B. Luo, The serum level and the genotype of TGF-β1 in patients with type 2 diabetic nephropathy. Chin. J. Lab. Med. 28, 73–77 (2005)
27.
Zurück zum Zitat M. Wei, Y.S. Lu, S.J. Li, H.C. She, Study of relationship between TGF-β Leu10Pro polymorphism and diabetic nephropathy in type 2 diabetes. Chin. J. Diabetes 16, 538–540 (2008) M. Wei, Y.S. Lu, S.J. Li, H.C. She, Study of relationship between TGF-β Leu10Pro polymorphism and diabetic nephropathy in type 2 diabetes. Chin. J. Diabetes 16, 538–540 (2008)
28.
Zurück zum Zitat K. Sharma, F.N. Ziyadeh, B. Alzahabi, T.A. McGowan, S. Kapoor, B.R. Kurnik, P.B. Kurnik, L.S. Weisberg, Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46, 854–859 (1997)PubMedCrossRef K. Sharma, F.N. Ziyadeh, B. Alzahabi, T.A. McGowan, S. Kapoor, B.R. Kurnik, P.B. Kurnik, L.S. Weisberg, Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46, 854–859 (1997)PubMedCrossRef
29.
Zurück zum Zitat K. Sharma, F.N. Ziyadeh, Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 267, F1094–F1101 (1994)PubMed K. Sharma, F.N. Ziyadeh, Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 267, F1094–F1101 (1994)PubMed
30.
Zurück zum Zitat B.B. Hoffman, K. Sharma, Y. Zhu, F.N. Ziyadeh, Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int. 54, 1107–1116 (1998)PubMedCrossRef B.B. Hoffman, K. Sharma, Y. Zhu, F.N. Ziyadeh, Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration. Kidney Int. 54, 1107–1116 (1998)PubMedCrossRef
31.
Zurück zum Zitat M. Suthanthiran, B. Li, J.O. Song, R. Ding, V.K. Sharma, J.E. Schwartz, P. August, Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc. Natl. Acad. Sci. USA 97, 3479–3484 (2000)PubMedCrossRef M. Suthanthiran, B. Li, J.O. Song, R. Ding, V.K. Sharma, J.E. Schwartz, P. August, Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc. Natl. Acad. Sci. USA 97, 3479–3484 (2000)PubMedCrossRef
32.
Zurück zum Zitat S. Helmig, A. Belwe, J. Schneider, Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. J. Investig. Med. 57, 655–661 (2009)PubMed S. Helmig, A. Belwe, J. Schneider, Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. J. Investig. Med. 57, 655–661 (2009)PubMed
33.
Zurück zum Zitat J. Gewaltig, K. Mangasser-Stephan, C. Gartung, S. Biesterfeld, A.M. Gressner, Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin. Chim. Acta. 316, 83–94 (2002)PubMedCrossRef J. Gewaltig, K. Mangasser-Stephan, C. Gartung, S. Biesterfeld, A.M. Gressner, Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin. Chim. Acta. 316, 83–94 (2002)PubMedCrossRef
34.
Zurück zum Zitat B.A. Perkins, L.H. Ficociello, K.H. Silva, D.M. Finkelstein, J.H. Warram, A.S. Krolewski, Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med. 348, 2285–2293 (2003)PubMedCrossRef B.A. Perkins, L.H. Ficociello, K.H. Silva, D.M. Finkelstein, J.H. Warram, A.S. Krolewski, Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med. 348, 2285–2293 (2003)PubMedCrossRef
35.
Zurück zum Zitat D.J. Newman, M.B. Mattock, A.B. Dawnay, S. Kerry, A. McGuire, M. Yaqoob, G.A. Hitman, C. Hawke, Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol. Assess. 9, iii–vi, xiii–163 (2005) D.J. Newman, M.B. Mattock, A.B. Dawnay, S. Kerry, A. McGuire, M. Yaqoob, G.A. Hitman, C. Hawke, Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol. Assess. 9, iii–vi, xiii–163 (2005)
Metadaten
Titel
Association between the T869C polymorphism of transforming growth factor-beta 1 and diabetic nephropathy: a meta-analysis
verfasst von
Hongxia Jia
Lili Yu
Bin Gao
Qiuhe Ji
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2011
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9503-0

Weitere Artikel der Ausgabe 3/2011

Endocrine 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.